Filtered By:
Condition: Thrombosis
Procedure: Heart Transplant

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 180 results found since Jan 2013.

New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the U.S. F...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Stroke in Patients with Left Ventricular Assist Devices
Background: Left ventricular assist devices (LVADs) are artificial pumps used in end-stage heart failure to support the circulatory system. These cardiac assist devices work in parallel to the heart, diverting blood from the left ventricle through an outflow graft and into the ascending aorta. LVADs have allowed patients with end-stage heart failure to live longer and with improved quality of life compared to best medical therapy alone. However, they are associated with significant risks related to both thrombosis and bleeding in this medically complex patient population. As LVADs continue to be used more widely, stroke ne...
Source: Cerebrovascular Diseases - September 10, 2021 Category: Neurology Source Type: research

Outflow cannula position for left ventricular assist device: A propensity score ‐matched study
ConclusionNo observed difference in mortality when adjusting for competing risk of heart transplantation. There was also no difference in stroke, pump thrombosis, driveline infection. Larger studies are required to confirm these findings. These preliminary data support the use of left-sided anastomoses to facilitate subsequent re-entry during heart transplantation.
Source: Journal of Cardiac Surgery - August 25, 2021 Category: Cardiovascular & Thoracic Surgery Authors: Khalil Jawad, Frank Koziarz, Alex Koziarz, Joanna N. Bouez, Naoto Fukunaga, Michael A. Borger, Vivek Rao Tags: ORIGINAL ARTICLE Source Type: research

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Troubleshooting Left Ventricular Assist Devices: Modern Technology and Its Limitations
AbstractPurpose of reviewAs the incidence of heart failure continues to rise, modern generation left ventricular assist devices (LVADs) have become the primary therapeutic modality used as both bridge to transplant (BTT) and destination therapy (DT) in patients with acute and chronic heart failure. This review aims to highlight the progression of LVAD technology, outline LVAD complications and manifestations, and provide evidence-based therapeutic methods to troubleshoot such adverse events.Recent findingsDespite modern innovation, LVAD adverse events continue to hinder the progress of HF paradigms and are associated with ...
Source: Current Treatment Options in Cardiovascular Medicine - August 2, 2021 Category: Cardiology Source Type: research

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Complications of left ventricular assist devices causing high urgency status on waiting list: impact on outcome after heart transplantation
ConclusionsLeft ventricular assist device therapy can impair the outcome after HTx. However, the occurrence of LVAD complications may not impact on outcome after HTx. Thus, we cannot support the prioritization or discrimination of HTx candidates according to distinct mechanical circulatory support ‐associated complications. Future allocation strategies have to respect that device‐related complications may define urgency but do not impact on the outcome after HTx.
Source: ESC Heart Failure - March 29, 2021 Category: Cardiology Authors: Moritz Benjamin Immohr, Udo Boeken, Franziska Mueller, Emir Prashovikj, Michiel Morshuis, Charlotte B öttger, Hug Aubin, Jan Gummert, Payam Akhyari, Artur Lichtenberg, René Schramm Tags: Original Research Article Source Type: research

Impact of Mitral Valve Prosthesis on Stroke after Insertion of Veno-Arterial Membrane Oxygenation for Postcardiotomy Shock
This study focused on stroke after valve surgery requiring VA-ECMO.
Source: The Journal of Heart and Lung Transplantation - March 20, 2021 Category: Transplant Surgery Authors: S. Ohira, D. Spielvogel, R. Malekan, J.B. Goldberg, P.J. Spencer, S.L. Lansman, M. Kai Tags: 1026 Source Type: research

Aortic and Renal Artery Thrombosis as the First Clinical Manifestation of COVID-19 in a Heart Transplant Recipient
The relation between coronavirus 2019 disease (COVID-19) and thrombotic events is well established, and both arterial and venous thrombotic events are described. Although arterial events occur in about 3.6 to 10.5% of critically ill patients, they are usually stroke or acute myocardial infarction. Arterial thrombosis of other sites is rare.
Source: The Journal of Heart and Lung Transplantation - March 20, 2021 Category: Transplant Surgery Authors: D.S. Belfort, C.R. Cafezeiro, D.A. Furlan, M.S. Lira, R.C. Dantas, C.A. Arag ão, I.W. Campos, M.S. Ávila, S. Mangini, L.B. Seguro, F.G. Marcondes-Braga, F. Bacal Tags: 1185 Source Type: research

A Comparative Analysis of Long-Term Outcomes in the MOMENTUM 3 Pivotal Trial and Continued Access Protocol Post-Approval Study Phase: A Study of over 1500 HeartMate 3 Implants
The MOMENTUM 3 pivotal trial conducted from 2014 to 2018 evaluated safety and effectiveness of the HeartMate 3 (HM3) left ventricular assist system (LVAS) compared to the HeartMate II pump. The trial demonstrated superiority of the HM3 LVAS for the primary endpoint of survival free of disabling stroke or reoperation to replace a malfunctioning pump at 2-years. HM3 LVAS superiority was due to improved hemocompatibility with near-elimination of device thrombosis, halving of stroke rates, and a decrease in gastrointestinal bleeding rates compared to the control device.
Source: The Journal of Heart and Lung Transplantation - March 20, 2021 Category: Transplant Surgery Authors: M.R. Mehra Tags: (4) Source Type: research

Simultaneous Multi-Vascular Bed Imaging in a Patient Supported by a Continuous-Flow LVAD
Patients supported with left ventricular assist devices (LVADs) are burdened by frequent hemocompatibility-related adverse events related to patient-pump interactions. These predominantly vascular events include stroke, gastrointestinal bleeding, and pump thrombosis. Our center performs routine, invasive hemodynamic ramp speed titrations in LVAD patients to determine the optimal rotational speed after implantation. We sought to interrogate changes in vascular hemodynamics during an exercise ramp study to understand the influence of pump speed and exercise on outflow graft and cerebrovascular flow.
Source: The Journal of Heart and Lung Transplantation - March 20, 2021 Category: Transplant Surgery Authors: I. Bole, D. Rodgers, B. Smith, A. Nguyen, B. Chung, S. Kalantari, N. Sarswat, G. Kim, T. Song, T. Ota, V. Jeevanandam, E. Kruse, C. Kordeck, C. Kramer, S. Pinney, J. Grinstein Tags: (1347) Source Type: research

Systemic tPA Treatment for Thrombosis in a Patient with Dilated Cardiomyopathy on Berlin Heart
We present a case of thrombosis in a patient on Berlin Heart LVAD that was successfully treated with systemic alteplase.
Source: The Journal of Heart and Lung Transplantation - March 20, 2021 Category: Transplant Surgery Authors: L.D. Glass, R. Murthy, P. Pastuszko Tags: (1357) Source Type: research

Propensity score ‐based analysis of long‐term outcome of patients on HeartWare and HeartMate 3 left ventricular assist device support
ConclusionsSurvival was not significantly different between both groups after PS matching, but was better for HM3, with a significantly lower incidence of haemorrhagic stroke and pump thrombosis for HM3. These results need to be interpreted carefully, because matching may have introduced greater imbalance on unmeasured covariates. A multicentre approach of carefully selected centres is recommended to enlarge the number of matched patients.
Source: ESC Heart Failure - February 26, 2021 Category: Cardiology Authors: Lieke Numan, Faiz Z. Ramjankhan, Daniel L. Oberski, Martinus I.F.J. Oerlemans, Emmeke Aarts, Monica Gianoli, Joris J. Van Der Heijden, Nicolaas De Jonge, Niels P. Van Der Kaaij, Christiaan L. Meuwese, Mostafa M. Mokhles, Anne ‐Marie Oppelaar, Tags: Original Research Article Source Type: research